CA2433057A1 - Variants de polypeptides de butyrylcholinesterase a efficacite accrue et methodes d'utilisation associees - Google Patents

Variants de polypeptides de butyrylcholinesterase a efficacite accrue et methodes d'utilisation associees Download PDF

Info

Publication number
CA2433057A1
CA2433057A1 CA002433057A CA2433057A CA2433057A1 CA 2433057 A1 CA2433057 A1 CA 2433057A1 CA 002433057 A CA002433057 A CA 002433057A CA 2433057 A CA2433057 A CA 2433057A CA 2433057 A1 CA2433057 A1 CA 2433057A1
Authority
CA
Canada
Prior art keywords
butyrylcholinesterase
seq
amino acid
nucleic acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002433057A
Other languages
English (en)
Inventor
Oksana Lockridge
Jeffry D. Watkins
James D. Pancook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska
Applied Molecular Evolution Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/748,739 external-priority patent/US7070973B2/en
Priority claimed from US10/032,233 external-priority patent/US20030153062A1/en
Application filed by Individual filed Critical Individual
Publication of CA2433057A1 publication Critical patent/CA2433057A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C12Q1/46—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase involving cholinesterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01008—Cholinesterase (3.1.1.8), i.e. butyrylcholine-esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne vingt cinq variants de butyrylcholinestérase présentant une activité hydrolytique de la cocaïne accrue, ainsi que les acides nucléiques codants associés. Cette invention concerne également des bibliothèques de variants de butyrylcholinestérase, ainsi que des bibliothèques des acides nucléiques correspondants codant des variants de butyrylcholinestérase. Enfin, cette invention concerne des méthodes permettant d'hydrolyser un substrat de butyrylcholinestérase à base de cocaïne, ainsi que des méthodes permettant de traiter un état induit par la cocaïne.
CA002433057A 2000-12-26 2001-12-21 Variants de polypeptides de butyrylcholinesterase a efficacite accrue et methodes d'utilisation associees Abandoned CA2433057A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/748,739 US7070973B2 (en) 2000-12-26 2000-12-26 Butyrylcholinesterase variants and methods of use
US09/748,739 2000-12-26
US10/032,233 2001-12-20
US10/032,233 US20030153062A1 (en) 2001-12-20 2001-12-20 Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
PCT/US2001/050450 WO2002064796A2 (fr) 2000-12-26 2001-12-21 Variants de polypeptides de butyrylcholinesterase a efficacite accrue et methodes d'utilisation associees

Publications (1)

Publication Number Publication Date
CA2433057A1 true CA2433057A1 (fr) 2002-08-22

Family

ID=26708157

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002433057A Abandoned CA2433057A1 (fr) 2000-12-26 2001-12-21 Variants de polypeptides de butyrylcholinesterase a efficacite accrue et methodes d'utilisation associees

Country Status (5)

Country Link
EP (1) EP1414974A2 (fr)
JP (1) JP4252311B2 (fr)
AU (1) AU2002248256B2 (fr)
CA (1) CA2433057A1 (fr)
WO (1) WO2002064796A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142875A (en) * 2001-04-30 2009-08-03 Avigdor Shafferman PEG-linked cholinesterases for the detoxification of circulating organophosphorus
GB2384239A (en) 2001-12-05 2003-07-23 Sense Proteomic Ltd Arrays of protein variants
US6989261B2 (en) * 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
GB0202018D0 (en) 2002-01-29 2002-03-13 Sense Proteomic Ltd Tag and method
BR0316865A (pt) * 2002-12-04 2005-10-25 Applied Molecular Evolution Variante de butirilcolinesterase, ácido nucleico, e, métodos para converter um derivado de camptotecina a um inibidor de topoisomerase, e para tratar câncer
WO2007146003A2 (fr) * 2006-06-07 2007-12-21 Human Biomolecular Research Institute Nouvelles méthodes de désintoxication d'un ester
WO2015168207A1 (fr) 2014-04-29 2015-11-05 Mayo Foundation For Medical Education And Research Cholinestérasiques possédant la capacité améliorée d'hydrolyser la ghréline acyle
US11865163B2 (en) 2016-09-15 2024-01-09 Mayo Foundation For Medical Education And Research Methods and materials for using butyrylcholinesterases to treat cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001625A (en) * 1995-05-19 1999-12-14 The United States Of America As Represented By The Secretary Of The Army Site-directed mutagenesis of esterases

Also Published As

Publication number Publication date
WO2002064796A2 (fr) 2002-08-22
JP2004535155A (ja) 2004-11-25
EP1414974A2 (fr) 2004-05-06
AU2002248256B2 (en) 2006-09-28
WO2002064796A8 (fr) 2003-11-13
WO2002064796A3 (fr) 2003-12-31
JP4252311B2 (ja) 2009-04-08

Similar Documents

Publication Publication Date Title
US20060063248A1 (en) Butyrylcholinesterase variants and methods of use
US10111937B2 (en) Method of reducing accumulation of intracellular tingible body macrophages
US7049121B2 (en) Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US6989261B2 (en) Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
AU2002248256B2 (en) Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use
AU2002248256A1 (en) Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use
US8318156B2 (en) Anti-***e compositions and treatment
US20050136044A1 (en) Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents
US20030153062A1 (en) Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US20080213281A1 (en) Butyrylcholinesterase Variants that Alter the Activity of Chemotherapeutic Agents
Masson et al. Mutation His322Asn in human acetylcholinesterase does not alter electrophoretic and catalytic properties of the erythrocyte enzyme
US20060019363A1 (en) Cytosolic phospholipase A2-beta enzymes
US20210277368A1 (en) Compositions and methods for treatment of chemical warfare agents
US6440683B1 (en) Cytosolic phospholipase A2-gamma enzymes and polynucleotides encoding same
AU2014201653B2 (en) Anti-***e compositions and treatment
Sun Characterization of human carboxylesterase CES1A1, CES2, and CES3; role in methylphenidate (Ritalin) metabolism
Loewenstein et al. Structure-function relationship studies in human cholinesterases reveal genomic origins for individual variations in cholinergic drug responses

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead